Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Review and Preview01:10

Review and Preview

8.4K
In statistics, several tools are used to interpret the data. Measures of central tendency represent the characteristics of the data, such as mean, median, and mode. Additionally, measures of variance like standard deviation and range are used to find the spread of data from the mean. Relative standing measures the distance between data locations. Commonly used measures of relative standings are percentile, z score, and quartiles.
Percentiles are a type of fractile that partition data into...
8.4K
Review and Preview01:13

Review and Preview

11.6K
Data are individual items of information obtained from a population or sample. Data may be classified as qualitative (categorical), quantitative continuous, or quantitative discrete. Because it is not practical to measure the entire population in a study, researchers use samples to represent the population. A random sample is a representative group from the population chosen by using a method that gives each individual in the population an equal chance of being included in the sample. Random...
11.6K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

462
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
462
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

165
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
165
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

275
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
275
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

262
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
262

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An integrated genetic approach prioritizes closely linked candidate genes underlying an open-field behavior QTL on chicken chromosome 1.

Poultry science·2026
Same authorSame journal

Triplet therapy with darolutamide and docetaxel for metastatic castration-sensitive prostate cancer: a multicenter real-world study.

Japanese journal of clinical oncology·2026
Same author

Non-destructive diagnosis of ambrosia beetle attacks via detection of the associated tree pathogens.

MethodsX·2026
Same author

Response to the comment on "Impact of malnutrition severity on activities of daily living recovery in patients hospitalized with COPD exacerbations: A prospective observational study".

Nutrition (Burbank, Los Angeles County, Calif.)·2026
Same author

Induced pluripotent stem cell-derived dendritic cells potentiate the efficacy of interleukin-12-expressing oncolytic HSV-1.

Molecular therapy. Oncology·2026
Same author

A Nomogram Predicts the Need for Internal Iliac Vein Dissection During Renal Transplantation: A Multicenter Collaborative Study.

Transplantation proceedings·2026

Related Experiment Video

Updated: Feb 11, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.3K

Drug review: Pazopanib.

Shingo Miyamoto1, Shigenori Kakutani2, Yujiro Sato2

  • 1Department of Medical Oncology.

Japanese Journal of Clinical Oncology
|April 24, 2018
PubMed
Summary

Pazopanib is an oral multi-kinase inhibitor approved for advanced soft-tissue sarcoma and renal cell carcinoma. While effective, it can cause adverse events, though these are manageable, improving quality of life and cost-effectiveness.

More Related Videos

Novel Apparatus and Method for Drug Reinforcement
07:32

Novel Apparatus and Method for Drug Reinforcement

Published on: August 20, 2010

20.0K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K

Related Experiment Videos

Last Updated: Feb 11, 2026

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

10.3K
Novel Apparatus and Method for Drug Reinforcement
07:32

Novel Apparatus and Method for Drug Reinforcement

Published on: August 20, 2010

20.0K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.2K

Area of Science:

  • Pharmacology
  • Oncology
  • Clinical Trials

Background:

  • Pazopanib is an oral multi-kinase inhibitor targeting VEGFR, PDGFR, and c-kit.
  • It has demonstrated anti-angiogenic properties in preclinical models.
  • Currently approved for advanced soft-tissue sarcoma and renal cell carcinoma.

Purpose of the Study:

  • To review clinical trial results and pharmacological actions of pazopanib.
  • To evaluate the current status of pazopanib by examining associated issues.
  • To assess its impact on health-related quality of life and cost-effectiveness.

Main Methods:

  • Review of published clinical trial data.
  • Analysis of pharmacological mechanisms of pazopanib.
  • Evaluation of adverse event profiles and patient-reported outcomes.

Main Results:

  • Pazopanib shows positive results in large-scale trials for soft-tissue sarcoma and renal cell carcinoma.
  • Common adverse events include liver dysfunction and hypertension, often leading to discontinuation.
  • The drug improves quality-adjusted life years and reduces treatment costs compared to alternatives.

Conclusions:

  • Pazopanib is an important therapeutic option for specific cancers.
  • Management of adverse events is crucial for treatment continuation.
  • Pazopanib offers a favorable balance of efficacy, quality of life, and cost-effectiveness.